No Data
No Data
HK stocks surge | Huakang Biomedical (08622) rose more than 40% in mid-day trading, planning to carry out online store and enzyme-based product trade business.
Huakang Biomedical (08622) rose more than 40% in intraday trading. As of press time, it has risen 31.63%, with a share price of HKD 0.129 and a turnover of HKD 0.401 million.
Huakang Biomed (08622.HK) plans to carry out enzyme-based product trade business involving online sales platforms and corporate-to-corporate trade operations of Enzyme Good Life Group (China) Co., Ltd.
On July 22, Gelonhui announced that Huakang Biomedical (08622.HK) plans to conduct enzyme-based product trading business ("new business activities") related to online sales platforms and enterprise-to-enterprise products for Haosheng Group (China) Co., Ltd. which is primarily engaged in the research and development, production, marketing and sales of in vitro diagnostic reagents, assisted reproductive supplies and equipment in China. The board of directors is actively exploring new business opportunities to bring higher returns to shareholders. Considering the sustained growth potential of enzyme-based products and e-commerce consumption in the domestic market in China in recent years, the directors believe that the implementation of new business activities will bring more opportunities for the group.
Huakang Biomed (08622) is carrying out new business activities.
Huakang Biomed (08622) announced that the group plans to conduct activities related to online sales platforms and enterprise-to-enterprise product trade...
Express News | Huakang Biomedical - Intends to Commence Trading Business of Enzyme- Based Products of Bestyzym + Bestlife Group (China)
HUAKANG BIOMED: DISCLOSEABLE TRANSACTION AND ADVANCE TO ENTITY REPAYMENT ARRANGEMENT IN RELATION TO ACQUISITION OF 19% EQUITY INTEREST OF THE TARGET COMPANY AND PROVISION OF LOAN
HUAKANG BIOMED: ANNUAL REPORT 2023
No Data